...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Q2 Zenith/Resverlogix Events
1
Apr 12, 2016 12:11PM
2
Apr 12, 2016 05:10PM

Hi Sanfran.

I do agree with you completely. Don said about a year ago or two that he would be doing quarterly updates but I am not at all surprised that he is not living up too his promise.

He could be updating us on topics like the following;

  1. Progress on the prostate trial.
  2. Known results to date on the prostate trial of zen3694.
  3. Progress on partnerships.
  4. Progress on potential revenue sources.
  5. Status of funding.
  6. Progress on an IPO, the structure of the IPO, etc.
  7. New findings from the blood sample testing.
  8. New compounds, new indications and potential new trials.
  9. Feedback from all of the conferences for scientific reactions and responses from the business community.
  10. The results of the private fund raising they did that required a minimum investment of $100,000.
  11. Etc.

This would not be difficult to do. It just requires commitment. It would also be an excellent communications document or the press, PR agencies, potential investors, etc.

Speaking of the press I wonder why both Zenith and RVX are getting ZERO coverage?

We can only hope.

Cheers

Toinv

Share
New Message
Please login to post a reply